-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Sanofi and Regeneron jointly announced that the PD-1 inhibitor Libtayo (cemiplimab) jointly developed by the two parties will be used as a monotherapy for the treatment of stage 3 patients with relapsed/metastatic cervical cancer.
Cervical cancer is the fourth leading cause of cancer deaths in women in the world, and it most often occurs in women aged 35-44.
Libtayo is a PD-1 inhibitor that enhances the anti-cancer immune response of T lymphocytes by blocking the binding of PD-1 and its ligand.
In this open-label, multi-center phase 3 clinical trial, patients with recurrent/metastatic cervical cancer who had progressed after platinum-containing chemotherapy were treated with Libtayo or chemotherapy selected by the investigator.
In the squamous cell carcinoma subgroup, Libtayo reduced the risk of death by 27%, while in the adenocarcinoma subgroup, Libtayo reduced the risk of death by 44%.
Note: The original text has been deleted
Reference materials:
[1] PHASE 3 TRIAL OF LIBTAYO® (CEMIPLIMAB) MONOTHERAPY IN ADVANCED CERVICAL CANCER STOPPED EARLY FOR POSITIVE RESULT ON OVERALL SURVIVAL.